AstraZeneca India said it has received Central Drugs Standard Control Organisation's approval to market the anti-diabetes medication, Dapagliflozin. Dapagliflozin is the first and only anti-diabetic drug approved to significantly reduce the risk of sustained eGFR, cardiovascular deaths and hospitalisations due to heart failure in adults with progressive chronic kidney disease (CKD), it said.